FIELD: medicine; pharmaceutics.
SUBSTANCE: invention relates to an antibody-drug conjugate, in which a cyclic dinucleotide derivative (CDN) having STING agonist activity is conjugated with an anti-target cell antibody by means of a linker, to a pharmaceutical composition containing said antibody-drug conjugate, and to a method of treating cancer associated with STING agonist activity.
EFFECT: novel conjugate of the antibody with a CDN derivative exhibits an anti-tumour effect on an antigen-expressing tumour.
30 cl, 24 dwg, 2 tbl, 28 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CONJUGATE OF ANTI-CEA ANTIBODY AND EXCATECAN ANALOGUE AND PHARMACEUTICAL USE THEREOF | 2020 |
|
RU2833323C1 |
| ANTI-B7-H4 ANTIBODY AND DRUG CONJUGATE AND MEDICAL USE THEREOF | 2020 |
|
RU2827531C2 |
| SULFOMALEIMIDE-BASED LINKERS AND CORRESPONDING CONJUGATES | 2019 |
|
RU2815199C2 |
| ANTIBODY AND DRUG CONJUGATES FOR DESTRUCTION OF HEMATOPOIETIC STEM CELLS | 2017 |
|
RU2781444C2 |
| CONJUGATE OF ANTI-CLAUDIN ANTIBODY AND MEDICINAL AGENT AND PHARMACEUTICAL USE THEREOF | 2020 |
|
RU2826119C1 |
| ANTI-BCMA ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF AND MEDICAL USE THEREOF | 2020 |
|
RU2819660C2 |
| ANTIBODY-DRUG CONJUGATE, INTERMEDIATE FOR ITS PRODUCTION, METHOD OF ITS PRODUCTION AND ITS USE | 2020 |
|
RU2800137C1 |
| ANTI-HER3 CONJUGATE ANTIBODY-DRUG | 2015 |
|
RU2802211C2 |
| PMEL17 ANTIBODIES AND CONJUGATES BASED THEREON | 2019 |
|
RU2831785C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF MALIGNANT TUMOR | 2017 |
|
RU2766586C2 |
